The beta-oxidation of arachidonic acid and the synthesis of docosahexaenoic acid are selectively and consistently altered in skin fibroblasts from three Zellweger patients versus X-adrenoleukodystrophy, Alzheimer and control subjects

Neurosci Lett. 1998 Jul 10;250(3):145-8. doi: 10.1016/s0304-3940(98)00467-4.

Abstract

The beta-oxidation of [3H] arachidonic acid (AA; 20:4 n-6) and the conversion of [1-14C]eicosapentaenoic acid (EPA, 20:5 n-3) to docosahexaenoic acid (DHA, 22:6 n-3) have been studied in skin fibroblasts from patients with inherited peroxisomal diseases, such as Zellweger (ZW) and X-linked adrenoleukodystrophy (X-ALD), from patients with Alzheimer's disease (AD), a non-inherited neuropathology, and from controls. EPA is not converted to DHA, while there is enhanced formation of the intermediate product 22:5 n-3 in ZW, when compared to X-ALD, AD and controls. We also confirmed that AA is not beta-oxidized to 4,7,10-hexadecatrienoic acid (16:3), a metabolite produced by peroxisomes, while being more effectively converted to the elongation product 22:4, in ZW, in comparison to X-ALD, AD and controls. The data demonstrate a defect in DHA synthesis and in AA beta-oxidation, and the occurrence of associated adaptative modifications in the metabolism of these long chain PUFA, in three Italian ZW patients.

Publication types

  • Comparative Study

MeSH terms

  • Adrenoleukodystrophy / metabolism*
  • Alzheimer Disease / metabolism*
  • Arachidonic Acid / metabolism*
  • Docosahexaenoic Acids / metabolism*
  • Fibroblasts / metabolism*
  • Humans
  • Oxidation-Reduction
  • Skin / cytology
  • Skin / metabolism*
  • Zellweger Syndrome / metabolism*

Substances

  • Docosahexaenoic Acids
  • Arachidonic Acid